![Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials - The Lancet Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/2003018872/2011627633/gr1.jpg)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials - The Lancet
![Cumulative incidence functions for breast cancer recurrence, second... | Download Scientific Diagram Cumulative incidence functions for breast cancer recurrence, second... | Download Scientific Diagram](https://www.researchgate.net/publication/49799336/figure/fig1/AS:667206274797572@1536085780398/Cumulative-incidence-functions-for-breast-cancer-recurrence-second-malignancy-and-death.png)
Cumulative incidence functions for breast cancer recurrence, second... | Download Scientific Diagram
![PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis](https://i1.rgstatic.net/publication/5461472_Healing_by_primary_closure_versus_open_healing_after_surgery_for_pilonidal_sinus_Systemic_review_and_meta-analysis/links/0deec514b36081b9fe000000/largepreview.png)
PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis
![Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials - The Lancet Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/cb0e4f55-fadb-4099-83aa-0cb253e27ec1/gr1_lrg.jpg)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials - The Lancet
![Cancers | Free Full-Text | (−)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models Cancers | Free Full-Text | (−)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models](https://www.mdpi.com/cancers/cancers-11-00637/article_deploy/html/images/cancers-11-00637-g001.png)
Cancers | Free Full-Text | (−)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models
![Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer | Scientific Reports Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep26304/MediaObjects/41598_2016_Article_BFsrep26304_Fig1_HTML.jpg)
Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer | Scientific Reports
![Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2092216225/2076440337/gr1.gif)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet
![Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer | Research To Practice Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_page_image/slideshow_page/33074/Slide1.jpg)